
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
In type 2 diabetes, GLP-1 agonists help lower blood sugar by increasing insulin release in a glucose dependent way and by slowing the liver’s production of glucose. They are commonly added to treatment plans when standard oral agents, including metformin, do not keep blood sugar within target. Certain GLP-1 medications have also been shown to cut the risk of serious heart events in patients who have both type 2 diabetes and known cardiovascular disease.
Among individuals who are overweight or obese but not diabetic, GLP-1 agonists like Wegovy and Saxenda are FDA approved tools for weight loss. These medications enhance satiety and suppress appetite, making it much easier for patients to reduce daily calorie intake and stick with nutrition plans. Clinical evidence shows that when GLP-1 treatment is combined with lifestyle modification, many patients see substantial and long lasting reductions in body weight.
GLP-1 receptor agonists work on blood sugar regulation by helping the pancreas release more insulin after meals while simultaneously decreasing glucagon levels. This two way mechanism helps avoid dramatic increases in blood glucose and promotes more stable overall control. Because these medications respond in a glucose dependent way, they are less likely to cause low blood sugar than many commonly used diabetes treatments.
A standout feature of GLP-1 therapy is its capacity to promote durable weight loss and ongoing weight maintenance. By delaying the emptying of the stomach and sending stronger fullness signals to the brain, these medications reduce hunger and cravings, making it easier to eat less without feeling deprived. Clinical trials have demonstrated that agents such as liraglutide, semaglutide, and tirzepatide can deliver substantial and long lasting weight loss when paired with lifestyle modifications.



By activating both GLP-1 and GIP receptors, GLP-1/GIP co-agonists improve insulin release and appetite control more efficiently than GLP-1 alone. These medications represent a powerful tool in regulating blood sugar and curbing hunger, proving to be effective in managing obesity and diabetes.
GLP-1/glucagon co-agonists work on both GLP-1 and glucagon receptors to promote weight loss and enhance energy metabolism while helping to preserve lean muscle mass, supporting long-term health and metabolic balance.

